Graves’ Disease - The Interaction of Lymphocytes and Thyroid Cells by Ben-Skowronek Iwona
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Graves’ Disease - The Interaction of 
Lymphocytes and Thyroid Cells  
Ben-Skowronek Iwona 
Medical University in Lublin,  
Poland 
1. Introduction 
Human autoimmune thyroid disorders (AITD), Graves’ disease (GD) and Hashimoto’s 
thyroiditis, are characterized by reactivity to self-thyroid antigens. Graves’ disease is the 
archetype for organ-specific autoimmune disorders, very important to our understanding 
the mechanisms responsible for progression of autoimmunity. 
It has been known for years that hyperthyroidism in Graves’disease is induced by 
immunological reaction, in which TSH receptor antibodies bind to the receptors on the 
surface of thyrocytes, activate them and initiate thyroid hormone production independent of 
the hypothalamic-hypophyseal control. It is known nowadays that, probably for 
environmental or endogenous reasons, Graves’disease may develop in genetically 
predisposed individuals [Weetman, 2004].  
2. Antigen presentation 
A small number of antigen presenting cells (APCs) as CD1a+ presenting dendritic cells (DC) 
were observed in the thyroids without AITD, but their number was significantly higher in 
the thyroids from Graves’ disease patients [Ben-Skowronek et al., 2007, 2008]. There are 
indications that such DCs are able to proliferate, which indicates that not all of the thyroid 
DCs need to have recently immigrated with the blood stream [Quadbeck et al. 2002]. CD1a 
antigen has the structure of an α-chain connected with β-microglobulins and is characteristic 
for immature APCs [Brigl & Brenner, 2004]. Thyroidal DCs are often in close contact with 
thyrocytes; they are clearly in an immature state and often show monocyte marker 
characteristics. The presence of positive reaction to CD1a protein in the granules of the 
apical part of some thyrocytes suggested that the thyrocytes may probably be antigen 
presenting cells in the thyroid autoimmune reactivity [Ben-Skowronek et al., 2007,2008]. The 
investigations of transgenic mice by Kimura et al. [Kimura et al., 2004] indicated that 
expression of class II MHC molecules on epithelial thyroid cells is not required for the 
initiation of an autoimmune attack to the thyroid. The initiation, then, seems to be mainly 
mediated by the professional antigen presenting cells in the lymphoid tissue. The antigen 
can be presented to CD4+ cells by conventional antigen presenting cells, particularly 
dendritic cells and also by B-cells and activated T-cells, and less effectively by thyrocytes. 
The antigen presentation by thyroid epithelial cells sustains the autoimmune reaction. 
 




Fig. 1. The thyrocytes are antigen presenting cells and show reaction with the CD1a 
monoclonal antibody. Magn. 400x 
While analyzing the process of antigen presentation in thyroids sampled from patients, the 
treatment process should be taken into account. Metimazole and carbimazole change the 
presentation of antigens by thyrocytes. Thionamides have been reported to influence the 
expression the antigens of the major histocompatibility complex class I, IL-1 (interleukin-1), 
IL-6 (interleukin- 6), prostaglandins E2 produced by thyrocytes [Zantut-Wittmann et al., 
2001]. The expression of major histocompatibility complex class II is unchanged by 
thionamides [Dedecjus et al. 2010].  
Numerous investigations indicate that adhesion molecules are engaged in the process of 
migration of lymphocytes to the thyroid and lymphocyte adhesion [Arao et al., 2000]. 
Adhesion molecule ICAM-1 (Inter-Cellular Adhesion Molecule 1) belonging to the 
superfamily IgG is a natural ligand of antigen located on lymphocytes LFA-1 (Lymphocytic 
function-associated antigen - 1). This antigen belongs to the integrin-β2 superfamily 
[Springer, 1990]. ICAM-1 is located on different cells: fibroblasts, endotheliocytes, and 
thymocytes. It was identified on thyrocytes as well [Weetman et al., 1989, Martin et al., 1990, 
Springer,1990].The expression of ICAM-1 is regulated by proinflammatory cytokines: 
interferon γ, interleukin 1β (IL 1β) and TNF-α ( Tumor Necrosis Factor -1) [Dustin et al., 
1986, Martin et al., 1990, Springer 1990, Bagnasco et al., 1991]. In Graves’ disease, the ICAM-
1/LFA-1 pathway plays a key role in migration and settlement of lymphocytes in the 
thyroid, and particularly in the process of adhesion of lymphocytes to thyrocytes [Arao et 
al.,2000]. In vitro experiments have shown that thyrocytes behave like antigen presenting 
cells and can induce lymphocyte migration [Estienne et al., 2002].  
Expression of HLA DR II and the immunoglobulin Fc receptor (FcγRIIB2) has been found on 
the basal and apical surfaces of thyrocytes [Botazzo et al., 1983, Wu et al., 1999]. The 
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presentation of the latter antigen is dependent on the low level of androgens, which is 
probably connected with higher prevalence of AITD in women [Estienne et al., 2002]. 
Presentation of antigens by thyrocytes without the costimulatory molecule B7 does not lead 
to activation of T-cells [Marelli-Berg et al., 1997]. The expression APC characteristic antigens 
are dependent on TSH [Todd et al., 1987, Estienne et al., 2004]. Thyrocytes may produce 
HLA I under the influence of cytokines of lymphocytes present in the thyroid. In this way, 
the autoimmunologic reaction is sustained [Catalfamo et al., 1999].  
3. The development of autoimmune reaction 
When immune tolerance to thyroid antigens is broken, the endothelial cells of regional 
postcapillary venules are activated, allowing extravasation of blood leukocytes. In Graves’ 
disease, the lymphatic tissue arranged in lymphoid follicles containing T- cells may be 
formed in the thyroid. T-cells form infiltrations and lymphatic follicles but do not damage 
thyrocytes [Kuby et al., 2007].  
Graves’ disease patients seem to have mixed Th1/Th2 profiles. The lymphocyte subsets 
produce signal interleukin: Th1 – IL2 and Th2- IL4.The immunological response proceeds 
via T-cell receptor (TCR) antigen recognition, followed by activation of the T- cell through a 
combined effect of antigen recognition and co-stimulatory signals, including interleukin -1 
(IL-1) action leading to T- cell IL 2 secretion and IL-2 receptor expression and, subsequently, 
to proliferation of the T- cell into an active clone. [Janeway et al., 2001 Janeway & Medzhitov 
2002] 
In Graves’ disease, the increased percentage of CD4+ T helper cells, in comparison to non-
AITD, leads to development of humoral autoimmune response. Antigens of self-thyrocytes 
are presented in such a way that they are recognized by self – T-helper CD4+ lymphocytes. 
T-helper cells CD4+ sporadic occurred in thyroids of children from the control group, 
seldom in the simple goiter and slightly more often in the nontoxic nodular goiter. The 
number of T-helper cells in Graves’ disease was the largest [Ben-Skowronek et al., 2007, 
2008]. 
The subset of CD4+cells includes the regulatory lymphocytes - Tregs, which play a 
fundamental role in modulation of immunological response through their inhibitive effect 
on autoreactive T-cells [Piccirillo & Shevach,2004, Piccirillo & Thornton, 2004, Shewach, 
2006]. The mechanism of this suppression is unknown, but many investigators consider it to 
be dependent on the contact between lymphocytes and independent of secretion of IL-10 
and TGFβ [Piccirillo et.al. 2002,2003]. In the remission phase during thyrotoxic treatment, 
the subsets of lymphocytes were not different from the control group and from children 
with the simple goiter and nontoxic goiter [Bossowski et al. 2003]. The cells were 
characterized by expression of CD25 (the α-chain of IL2) and intracellular expression of 
FoxP3 (Forkhead winged helix box3). Only the subset of CD4+cells with maximal expression 
of CD25 (CD4+CD25+high) is responsible for the suppressor – regulatory effect of these 
lymphocytes [Cao et al., 2003, Baecher-Allan et al., 2001, 2003, Bossowski 2010]. The 
CD4+CD25+ cells can occur natural or can be induced – they are generated in the lymphatic 
tissue from CD4+CD25+ cells by different stimulant agents: by immature dendritic cells, IL-
10, TGFβ, supply of vitamin D3 or dexamethasone, anti-lymphatic treatment or small doses 
of antigens. The Treg cells not need costimulation of CD28-B7 for their development or 
activity. They play a pivotal role in sustenance of immunologic tolerance [Piccirillo & 
Shewach, 2004, Piccirillo & Thornton, 2004]. TGF-β is assumed to be necessary for the 
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regulatory function of Treg cells; it also prevents activation of lymphocytes and 
autoimmune reactions [Bommireddy et al., 2008]. The quantity of lymphocytes in this subset 
is decreased in Graves’ disease [Deshun et al., 2009].   
An increase in T-helper lymphocytes, especially in Th1 lymphocytes, results in activation 
of B lymphocytes and their transformation into plasma cells which produce thyroid 
antibodies, predominantly TRAB (TSH receptor antibody), TSI ( TSH stimulated 
immunoglobulin), and also TPO Ab ( Antithyroperoxidase antibody) and TG Ab ( 
Antithyroglobulin antibody). 
T cells CD8+ are observed in the thyroid more often in Graves’ disease than in non-AITD; 
they have a regulatory T-cell function. Electron microscopy examinations did not 
demonstrate any damage to thyrocytes, but CD8+ lymphocytes frequently entered the 
thyroid follicles through the basal membrane [Ben-Skowronek et al., 2009].  
The T-suppressor-cytotoxic CD8+ cells were observed in thyroid follicles between 
thyrocytes, in mononuclear infiltrations and in lymphatic follicles in the mantle zone. In 
light microscopy, CD8+ T-cells and adherent normal thyrocytes were visible in high 
magnifications. Bossowski et al. have found a correlation between expression of 
costimulatory molecules CTLA-4 and CD28 on T-cells and the level of antibodies against the 
TSH receptor [Bossowski et al., 2005]. The investigations of Negrini et al. [Negrini et al., 
2006] indicate a possibility of presentation of GITR receptors on the surface T-cells CD8+ 
characteristic for Treg cells. Own observations have confirmed this character of CD8+ T-
cells, because they are located between thyrocytes and do not cause apoptosis. 
 
 
Fig. 2. The CD8+ T-cell between thyrocytes in thyroid follicle wall. The thyrocytes are active 
and present no signs of apoptosis or cell damage. Magn. 400x. 
In vitro investigations and observations of the thyroid tissue in electron microscopy indicate 
the possibility of formation of the so-called immunological synapse of a character of a tight 
junction between lymphocytes and thyrocytes with participation of adhesive proteins. This 
physical contact may result in establishment of an immunological synapse able to stimulate 
intra thyroid T lymphocyte proliferation and differentiation. 
 




Fig. 3. T cells among thyrocytes in the thyroid epithelium. The thyrocytes are active without 
destruction signs. N- nucleus, Mv – microvilli, BM – basal membrane, BV – blood vessel. 
Transmission Electron Microscopy Magn. 15 000x. 
Recent investigations have suggested that a crucial role in peripheral tolerance or 
autoreactive T- cells is played by T regulatory subsets (Tregs) divided into two populations: 
naturally occurring and inducible [Wieczorek et al., 2009]. Tregs so far identified as 
participating in the pathogenesis of Graves’ disease include naturally occurring 
CD4+,CD25+T cells , C8+CD122+T cells and natural killer cells [Bossowski et al., 2010]. 
Comparison of immunohistochemical localization of CD4+ T cells in ultrastructural 
investigations has shown that lymphocytes CD4+T were small cells with large nuclei and a 
small amount of cytoplasm in contact with thyrocytes and other lymphocytes [Ben-
Skowronek et al., 2009].  
 
 
Fig. 4. The immunological synapse between T-cells and thytrocytes in Graves’ disease. 
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Rifa’i et al. [Rifa’i et al., 2004] have described subsets of naturally occurring Tregs 
CD8+CD25+. It is possible that CD8+T cells in contact with thyrocytes play the role of Tregs 
in the pathogenesis of Graves’ disease. The investigations of Negrini et al. [ Negrini et al. 
2006] have characterized a subpopulation of CD8 T suppressor lymphocytes able to inhibit 
both cell proliferation and cytotoxicity; they have observed that glucocorticoid–induced 
TNF-like receptor (GITR) is expressed on such CD8 T suppressor cells. The papers of 
Nakano et al. [Nakano et al., 2006] and Nagayama [Nagayama et al., 2007] suggest a 
preventive role of Tregs in autoimmune reaction in the thyroid with AITD. 
Patients with Graves’ disease have an increased number of circulating B-cells but plasma 
cells predominate in the thyroid. The close contact with T-cells (probably Th2 cells) and 
plasma cells has been frequently observed only in Graves’ disease and sporadically in the 
non-AITD and suggested the regulation function of the T-cells stimulating plasma cells to 
produce autoantibodies [Ben-Skowronek et al., 2008].  
The plasma cells in Graves’ disease penetrate between thyreocytes; nevertheless, they 
caused no destruction of thyroid follicles and epithelial cells. Ultrastructural changes in 
plasma cells were observed in patients with Graves’ disease: a large, active nucleus with a 
nucleolus, a well-developed rough endoplasmic reticulum in which antibodies were 
 
 
Fig. 5. The plasma cell producing antibodies in contact with thyrocytes. RBC-red blood cell, 
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produced. The number of plasma cells in the thyroid was inversely proportional to time of 
treatment, which proved the immunomodulant activity of thyrostatic drugs [Ben-
Skowronek et al., 2009].  
In Graves’ disease, the immunological deposits observed in the basal membrane of the 
thyroid follicles lead to thickening of this membrane and probably to changes in 
polarization of cell membranes. The thyrocytes in this region are columnar, with signs of 
increased activity (big nuclei; active, enlarged mitochondria; a big number of granules in the 
apical pole; long microvilli). [ Ben-Skowronek et al., 2008,2009]. The antibody deposits do 
not damage thyrocytes but enhance their activity and metabolism by activation of the THS 
receptors, and lead to hyperthyroidism. 
 
 
Fig. 6. The late phase of development of antibodies deposits in the basal membrane of the 
thyrocytes. Transmission Electron Microscopy Magn. 20 00x 
Numerous reports have shown that Th-1 cell activating the antibody-dependent cellular 
cytotoxicity (ADCC) can be detected in Graves’ disease, although the response is usually 
weak and not present in many patients [Guo et al., 1997, Metcalfe et al., 1997]. ADCC of 
thyroid cells is induced by anti TPO antibody positive sera, but other unknown antibody-
antigen systems and methimazole therapy also contribute. Large granular lymphocytes – 
phenotypic NK cells - are rarely present in the lumen of the thyroid follicle. Here, 
degenerative changes in the thyrocytes were observed by electron microscopy [Ben-
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Antibodies may be produced against the TSH receptor (TSH receptor stimulating antibodies 
– TS Ab, TSH binding inhibiton immunoglobulins – TBII, TSH stimulation blocking 
antibodies – TSBAb), against thyroperoxidase (TPO Ab), against thyroglobulin (TG Ab), 
against megalin [Marino et al., 1999], against the iodine symporter, against thyroid’s DNA, 
against components of external eye muscles and fibroblasts, against parietal cells and 
against platelets [Weetmann, 2004].  
The stimulating antibodies (TSAb) react with the TSH receptor and initiate activity of adenyl 
cyclase and phospholipase A2of the receptor, thus stimulating production of thyroid 
hormones and growth and division of thyrocytes [Orgiazzi et al.,1976, DiCerbo et al., 1999, 
Ewans et al.,1999, Morshed et al., 2009]. The blocking antibodies act like weak agonists of 
the TSH receptor [Lenzner et al., 2003, Schwarz-Lauer et al., 2002]. 
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